MedTrace Logo

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

NCT06340750 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-06-03

No results posted yet for this study

Summary

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.

Conditions

Interventions

BIOLOGICAL

LMY-920

CAR T Therapy

Sponsors & Collaborators

  • Nationwide Children

    collaborator UNKNOWN

  • Luminary Therapeutics

    lead INDUSTRY

Principal Investigators

  • Dean Lee, PhD · Nationwide Children

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-04-15
Completion
2026-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06340750 on ClinicalTrials.gov